Global Pulmonary Arterial Hypertension (PAH) Drugs Market Insights and Forecast to 2026

Publisher Name :
Date: 01-Jul-2020
No. of pages: 145
Inquire Before Buying

Pulmonary Arterial Hypertension (PAH) Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Pulmonary Arterial Hypertension (PAH) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Pulmonary Arterial Hypertension (PAH) Drugs market is segmented into

- Inhalation

- Injectables

- Oral Administration

Segment by Application, the Pulmonary Arterial Hypertension (PAH) Drugs market is segmented into

- Hospitals

- Clinics

- Other

Regional and Country-level Analysis

The Pulmonary Arterial Hypertension (PAH) Drugs market is analysed and market size information is provided by regions (countries).

The key regions covered in the Pulmonary Arterial Hypertension (PAH) Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape and Pulmonary Arterial Hypertension (PAH) Drugs Market Share Analysis

Pulmonary Arterial Hypertension (PAH) Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Pulmonary Arterial Hypertension (PAH) Drugs business, the date to enter into the Pulmonary Arterial Hypertension (PAH) Drugs market, Pulmonary Arterial Hypertension (PAH) Drugs product introduction, recent developments, etc.

The major vendors covered:

- Pfizer

- Glaxosmithkline

- Novartis

- United Therapeutics

- AstraZeneca

- Merck

- Bayer Healthcare

- Actelion Pharmaceuticals

- Daiichi Sankyo

- Northern Therapeutics

- Aires Pharmaceuticals

- Arena Pharmaceuticals

- Berlin Cures

- Eiger BioPharmaceuticals

- Reata Pharmaceuticals

Global Pulmonary Arterial Hypertension (PAH) Drugs Market Insights and Forecast to 2026

Table of Contents
1 Study Coverage
1.1 Pulmonary Arterial Hypertension (PAH) Drugs Product Introduction
1.2 Market Segments
1.3 Key Pulmonary Arterial Hypertension (PAH) Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate by Type
1.4.2 Inhalation
1.4.3 Injectables
1.4.4 Oral Administration
1.5 Market by Application
1.5.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate by Application
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size, Estimates and Forecasts
2.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue 2015-2026
2.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales 2015-2026
2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Pulmonary Arterial Hypertension (PAH) Drugs Competitor Landscape by Players
3.1 Pulmonary Arterial Hypertension (PAH) Drugs Sales by Manufacturers
3.1.1 Pulmonary Arterial Hypertension (PAH) Drugs Sales by Manufacturers (2015-2020)
3.1.2 Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Manufacturers (2015-2020)
3.2 Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Manufacturers
3.2.1 Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Manufacturers (2015-2020)
3.2.2 Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Pulmonary Arterial Hypertension (PAH) Drugs Revenue in 2019
3.2.5 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Pulmonary Arterial Hypertension (PAH) Drugs Price by Manufacturers
3.4 Pulmonary Arterial Hypertension (PAH) Drugs Manufacturing Base Distribution, Product Types
3.4.1 Pulmonary Arterial Hypertension (PAH) Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Pulmonary Arterial Hypertension (PAH) Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Pulmonary Arterial Hypertension (PAH) Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Type (2015-2020)
4.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2015-2020)
4.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2015-2020)
4.1.3 Pulmonary Arterial Hypertension (PAH) Drugs Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Forecast by Type (2021-2026)
4.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Type (2021-2026)
4.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Forecast by Type (2021-2026)
4.2.3 Pulmonary Arterial Hypertension (PAH) Drugs Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Application (2015-2020)
5.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2015-2020)
5.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Application (2015-2020)
5.1.3 Pulmonary Arterial Hypertension (PAH) Drugs Price by Application (2015-2020)
5.2 Pulmonary Arterial Hypertension (PAH) Drugs Market Size Forecast by Application (2021-2026)
5.2.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Application (2021-2026)
5.2.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Forecast by Application (2021-2026)
5.2.3 Global Pulmonary Arterial Hypertension (PAH) Drugs Price Forecast by Application (2021-2026)
6 North America
6.1 North America Pulmonary Arterial Hypertension (PAH) Drugs by Country
6.1.1 North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country
6.1.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures by Type
6.3 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures by Application
7 Europe
7.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs by Country
7.1.1 Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country
7.1.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures by Type
7.3 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs by Region
8.1.1 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region
8.1.2 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures by Type
8.3 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures by Application
9 Latin America
9.1 Latin America Pulmonary Arterial Hypertension (PAH) Drugs by Country
9.1.1 Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country
9.1.2 Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures by Type
9.3 Central & South America Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs by Country
10.1.1 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country
10.1.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures by Type
10.3 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Facts & Figures by Application
11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Corporation Information
11.1.2 Pfizer Description and Business Overview
11.1.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
11.1.5 Pfizer Related Developments
11.2 Glaxosmithkline
11.2.1 Glaxosmithkline Corporation Information
11.2.2 Glaxosmithkline Description and Business Overview
11.2.3 Glaxosmithkline Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
11.2.5 Glaxosmithkline Related Developments
11.3 Novartis
11.3.1 Novartis Corporation Information
11.3.2 Novartis Description and Business Overview
11.3.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Novartis Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
11.3.5 Novartis Related Developments
11.4 United Therapeutics
11.4.1 United Therapeutics Corporation Information
11.4.2 United Therapeutics Description and Business Overview
11.4.3 United Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.4.4 United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
11.4.5 United Therapeutics Related Developments
11.5 AstraZeneca
11.5.1 AstraZeneca Corporation Information
11.5.2 AstraZeneca Description and Business Overview
11.5.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.5.4 AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
11.5.5 AstraZeneca Related Developments
11.6 Merck
11.6.1 Merck Corporation Information
11.6.2 Merck Description and Business Overview
11.6.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Merck Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
11.6.5 Merck Related Developments
11.7 Bayer Healthcare
11.7.1 Bayer Healthcare Corporation Information
11.7.2 Bayer Healthcare Description and Business Overview
11.7.3 Bayer Healthcare Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
11.7.5 Bayer Healthcare Related Developments
11.8 Actelion Pharmaceuticals
11.8.1 Actelion Pharmaceuticals Corporation Information
11.8.2 Actelion Pharmaceuticals Description and Business Overview
11.8.3 Actelion Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
11.8.5 Actelion Pharmaceuticals Related Developments
11.9 Daiichi Sankyo
11.9.1 Daiichi Sankyo Corporation Information
11.9.2 Daiichi Sankyo Description and Business Overview
11.9.3 Daiichi Sankyo Sales, Revenue and Gross Margin (2015-2020)
11.9.4 Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
11.9.5 Daiichi Sankyo Related Developments
11.10 Northern Therapeutics
11.10.1 Northern Therapeutics Corporation Information
11.10.2 Northern Therapeutics Description and Business Overview
11.10.3 Northern Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
11.10.5 Northern Therapeutics Related Developments
11.1 Pfizer
11.1.1 Pfizer Corporation Information
11.1.2 Pfizer Description and Business Overview
11.1.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Products Offered
11.1.5 Pfizer Related Developments
11.12 Arena Pharmaceuticals
11.12.1 Arena Pharmaceuticals Corporation Information
11.12.2 Arena Pharmaceuticals Description and Business Overview
11.12.3 Arena Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Arena Pharmaceuticals Products Offered
11.12.5 Arena Pharmaceuticals Related Developments
11.13 Berlin Cures
11.13.1 Berlin Cures Corporation Information
11.13.2 Berlin Cures Description and Business Overview
11.13.3 Berlin Cures Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Berlin Cures Products Offered
11.13.5 Berlin Cures Related Developments
11.14 Eiger BioPharmaceuticals
11.14.1 Eiger BioPharmaceuticals Corporation Information
11.14.2 Eiger BioPharmaceuticals Description and Business Overview
11.14.3 Eiger BioPharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Eiger BioPharmaceuticals Products Offered
11.14.5 Eiger BioPharmaceuticals Related Developments
11.15 Reata Pharmaceuticals
11.15.1 Reata Pharmaceuticals Corporation Information
11.15.2 Reata Pharmaceuticals Description and Business Overview
11.15.3 Reata Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.15.4 Reata Pharmaceuticals Products Offered
11.15.5 Reata Pharmaceuticals Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Pulmonary Arterial Hypertension (PAH) Drugs Market Estimates and Projections by Region
12.1.1 Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Regions 2021-2026
12.1.2 Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Forecast by Regions 2021-2026
12.2 North America Pulmonary Arterial Hypertension (PAH) Drugs Market Size Forecast (2021-2026)
12.2.1 North America: Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast (2021-2026)
12.2.2 North America: Pulmonary Arterial Hypertension (PAH) Drugs Revenue Forecast (2021-2026)
12.2.3 North America: Pulmonary Arterial Hypertension (PAH) Drugs Market Size Forecast by Country (2021-2026)
12.3 Europe Pulmonary Arterial Hypertension (PAH) Drugs Market Size Forecast (2021-2026)
12.3.1 Europe: Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast (2021-2026)
12.3.2 Europe: Pulmonary Arterial Hypertension (PAH) Drugs Revenue Forecast (2021-2026)
12.3.3 Europe: Pulmonary Arterial Hypertension (PAH) Drugs Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Pulmonary Arterial Hypertension (PAH) Drugs Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Pulmonary Arterial Hypertension (PAH) Drugs Market Size Forecast by Region (2021-2026)
12.5 Latin America Pulmonary Arterial Hypertension (PAH) Drugs Market Size Forecast (2021-2026)
12.5.1 Latin America: Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast (2021-2026)
12.5.2 Latin America: Pulmonary Arterial Hypertension (PAH) Drugs Revenue Forecast (2021-2026)
12.5.3 Latin America: Pulmonary Arterial Hypertension (PAH) Drugs Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Pulmonary Arterial Hypertension (PAH) Drugs Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Pulmonary Arterial Hypertension (PAH) Drugs Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter's Five Forces Analysis
13.5 Primary Interviews with Key Pulmonary Arterial Hypertension (PAH) Drugs Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Pulmonary Arterial Hypertension (PAH) Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
List of Tables
Table 1. Pulmonary Arterial Hypertension (PAH) Drugs Market Segments
Table 2. Ranking of Global Top Pulmonary Arterial Hypertension (PAH) Drugs Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of Inhalation
Table 5. Major Manufacturers of Injectables
Table 6. Major Manufacturers of Oral Administration
Table 7. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 8. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 9. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Regions 2015-2020 (K Pcs)
Table 10. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Regions (2015-2020)
Table 11. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Regions 2015-2020 (US$ Million)
Table 12. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Manufacturers (2015-2020) (K Pcs)
Table 13. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Manufacturers (2015-2020)
Table 14. Global Pulmonary Arterial Hypertension (PAH) Drugs Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 15. Global Pulmonary Arterial Hypertension (PAH) Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pulmonary Arterial Hypertension (PAH) Drugs as of 2019)
Table 16. Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Manufacturers (2015-2020) (US$ Million)
Table 17. Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Manufacturers (2015-2020)
Table 18. Key Manufacturers Pulmonary Arterial Hypertension (PAH) Drugs Price (2015-2020) (USD/Pcs)
Table 19. Pulmonary Arterial Hypertension (PAH) Drugs Manufacturers Manufacturing Base Distribution and Headquarters
Table 20. Manufacturers Pulmonary Arterial Hypertension (PAH) Drugs Product Type
Table 21. Date of International Manufacturers Enter into Pulmonary Arterial Hypertension (PAH) Drugs Market
Table 22. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 23. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2015-2020) (K Pcs)
Table 24. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Type (2015-2020)
Table 25. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Type (2015-2020) (US$ Million)
Table 26. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Share by Type (2015-2020)
Table 27. Pulmonary Arterial Hypertension (PAH) Drugs Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 28. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2015-2020) (K Pcs)
Table 29. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Application (2015-2020)
Table 30. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2015-2020) (K Pcs)
Table 31. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Country (2015-2020)
Table 32. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2015-2020) (US$ Million)
Table 33. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Country (2015-2020)
Table 34. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2015-2020) (K Pcs)
Table 35. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2015-2020)
Table 36. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2015-2020) (K Pcs)
Table 37. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2015-2020)
Table 38. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2015-2020) (K Pcs)
Table 39. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Country (2015-2020)
Table 40. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2015-2020) (US$ Million)
Table 41. Europe Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Country (2015-2020)
Table 42. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2015-2020) (K Pcs)
Table 43. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2015-2020)
Table 44. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2015-2020) (K Pcs)
Table 45. Europe Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2015-2020)
Table 46. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Region (2015-2020) (K Pcs)
Table 47. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Region (2015-2020)
Table 48. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Region (2015-2020) (US$ Million)
Table 49. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Region (2015-2020)
Table 50. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2015-2020) (K Pcs)
Table 51. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2015-2020)
Table 52. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2015-2020) (K Pcs)
Table 53. Asia Pacific Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2015-2020)
Table 54. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2015-2020) (K Pcs)
Table 55. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Country (2015-2020)
Table 56. Latin Americaa Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2015-2020) (US$ Million)
Table 57. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Country (2015-2020)
Table 58. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2015-2020) (K Pcs)
Table 59. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2015-2020)
Table 60. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2015-2020) (K Pcs)
Table 61. Latin America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2015-2020)
Table 62. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Country (2015-2020) (K Pcs)
Table 63. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Country (2015-2020)
Table 64. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue by Country (2015-2020) (US$ Million)
Table 65. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Country (2015-2020)
Table 66. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Type (2015-2020) (K Pcs)
Table 67. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2015-2020)
Table 68. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales by Application (2015-2020) (K Pcs)
Table 69. Middle East and Africa Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2015-2020)
Table 70. Pfizer Corporation Information
Table 71. Pfizer Description and Major Businesses
Table 72. Pfizer Pulmonary Arterial Hypertension (PAH) Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 73. Pfizer Product
Table 74. Pfizer Recent Development
Table 75. Glaxosmithkline Corporation Information
Table 76. Glaxosmithkline Description and Major Businesses
Table 77. Glaxosmithkline Pulmonary Arterial Hypertension (PAH) Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 78. Glaxosmithkline Product
Table 79. Glaxosmithkline Recent Development
Table 80. Novartis Corporation Information
Table 81. Novartis Description and Major Businesses
Table 82. Novartis Pulmonary Arterial Hypertension (PAH) Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 83. Novartis Product
Table 84. Novartis Recent Development
Table 85. United Therapeutics Corporation Information
Table 86. United Therapeutics Description and Major Businesses
Table 87. United Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 88. United Therapeutics Product
Table 89. United Therapeutics Recent Development
Table 90. AstraZeneca Corporation Information
Table 91. AstraZeneca Description and Major Businesses
Table 92. AstraZeneca Pulmonary Arterial Hypertension (PAH) Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 93. AstraZeneca Product
Table 94. AstraZeneca Recent Development
Table 95. Merck Corporation Information
Table 96. Merck Description and Major Businesses
Table 97. Merck Pulmonary Arterial Hypertension (PAH) Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 98. Merck Product
Table 99. Merck Recent Development
Table 100. Bayer Healthcare Corporation Information
Table 101. Bayer Healthcare Description and Major Businesses
Table 102. Bayer Healthcare Pulmonary Arterial Hypertension (PAH) Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 103. Bayer Healthcare Product
Table 104. Bayer Healthcare Recent Development
Table 105. Actelion Pharmaceuticals Corporation Information
Table 106. Actelion Pharmaceuticals Description and Major Businesses
Table 107. Actelion Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 108. Actelion Pharmaceuticals Product
Table 109. Actelion Pharmaceuticals Recent Development
Table 110. Daiichi Sankyo Corporation Information
Table 111. Daiichi Sankyo Description and Major Businesses
Table 112. Daiichi Sankyo Pulmonary Arterial Hypertension (PAH) Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 113. Daiichi Sankyo Product
Table 114. Daiichi Sankyo Recent Development
Table 115. Northern Therapeutics Corporation Information
Table 116. Northern Therapeutics Description and Major Businesses
Table 117. Northern Therapeutics Pulmonary Arterial Hypertension (PAH) Drugs Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 118. Northern Therapeutics Product
Table 119. Northern Therapeutics Recent Development
Table 120. Aires Pharmaceuticals Corporation Information
Table 121. Aires Pharmaceuticals Description and Major Businesses
Table 122. Aires Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 123. Aires Pharmaceuticals Product
Table 124. Aires Pharmaceuticals Recent Development
Table 125. Arena Pharmaceuticals Corporation Information
Table 126. Arena Pharmaceuticals Description and Major Businesses
Table 127. Arena Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 128. Arena Pharmaceuticals Product
Table 129. Arena Pharmaceuticals Recent Development
Table 130. Berlin Cures Corporation Information
Table 131. Berlin Cures Description and Major Businesses
Table 132. Berlin Cures Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 133. Berlin Cures Product
Table 134. Berlin Cures Recent Development
Table 135. Eiger BioPharmaceuticals Corporation Information
Table 136. Eiger BioPharmaceuticals Description and Major Businesses
Table 137. Eiger BioPharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 138. Eiger BioPharmaceuticals Product
Table 139. Eiger BioPharmaceuticals Recent Development
Table 140. Reata Pharmaceuticals Corporation Information
Table 141. Reata Pharmaceuticals Description and Major Businesses
Table 142. Reata Pharmaceuticals Pulmonary Arterial Hypertension (PAH) Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 143. Reata Pharmaceuticals Product
Table 144. Reata Pharmaceuticals Recent Development
Table 145. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Regions (2021-2026) (K Pcs)
Table 146. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share Forecast by Regions (2021-2026)
Table 147. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 148. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share Forecast by Regions (2021-2026)
Table 149. North America: Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 150. North America: Pulmonary Arterial Hypertension (PAH) Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 151. Europe: Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 152. Europe: Pulmonary Arterial Hypertension (PAH) Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 153. Asia Pacific: Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Region (2021-2026) (K Pcs)
Table 154. Asia Pacific: Pulmonary Arterial Hypertension (PAH) Drugs Revenue Forecast by Region (2021-2026) (US$ Million)
Table 155. Latin America: Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 156. Latin America: Pulmonary Arterial Hypertension (PAH) Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 157. Middle East and Africa: Pulmonary Arterial Hypertension (PAH) Drugs Sales Forecast by Country (2021-2026) (K Pcs)
Table 158. Middle East and Africa: Pulmonary Arterial Hypertension (PAH) Drugs Revenue Forecast by Country (2021-2026) (US$ Million)
Table 159. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 160. Key Challenges
Table 161. Market Risks
Table 162. Main Points Interviewed from Key Pulmonary Arterial Hypertension (PAH) Drugs Players
Table 163. Pulmonary Arterial Hypertension (PAH) Drugs Customers List
Table 164. Pulmonary Arterial Hypertension (PAH) Drugs Distributors List
Table 165. Research Programs/Design for This Report
Table 166. Key Data Information from Secondary Sources
Table 167. Key Data Information from Primary Sources
List of Figures
Figure 1. Pulmonary Arterial Hypertension (PAH) Drugs Product Picture
Figure 2. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type in 2020 & 2026
Figure 3. Inhalation Product Picture
Figure 4. Injectables Product Picture
Figure 5. Oral Administration Product Picture
Figure 6. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application in 2020 & 2026
Figure 7. Hospitals
Figure 8. Clinics
Figure 9. Other
Figure 10. Pulmonary Arterial Hypertension (PAH) Drugs Report Years Considered
Figure 11. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size 2015-2026 (US$ Million)
Figure 12. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales 2015-2026 (K Pcs)
Figure 13. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Size Market Share by Region: 2020 Versus 2026
Figure 14. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Region (2015-2020)
Figure 15. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Region in 2019
Figure 16. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Region (2015-2020)
Figure 17. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Region in 2019
Figure 18. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Share by Manufacturer in 2019
Figure 19. The Top 10 and 5 Players Market Share by Pulmonary Arterial Hypertension (PAH) Drugs Revenue in 2019
Figure 20. Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 21. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type (2015-2020)
Figure 22. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Type in 2019
Figure 23. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Type (2015-2020)
Figure 24. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Type in 2019
Figure 25. Global Pulmonary Arterial Hypertension (PAH) Drugs Market Share by Price Range (2015-2020)
Figure 26. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application (2015-2020)
Figure 27. Global Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Application in 2019
Figure 28. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Application (2015-2020)
Figure 29. Global Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Application in 2019
Figure 30. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Growth Rate 2015-2020 (K Pcs)
Figure 31. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Growth Rate 2015-2020 (US$ Million)
Figure 32. North America Pulmonary Arterial Hypertension (PAH) Drugs Sales Market Share by Country in 2019
Figure 33. North America Pulmonary Arterial Hypertension (PAH) Drugs Revenue Market Share by Country in 2019
Figure 34. U.S. Pulmonary Arterial Hypertensi
  • Global Pulmonary Arterial Hypertension (Pah) Medicine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 04-Jan-2024        Price: US 3380 Onwards        Pages: 103
    Market Overview of Global Pulmonary Arterial Hypertension (Pah) Medicine market: According to our latest research, the global Pulmonary Arterial Hypertension (Pah) Medicine market looks promising in the next 5 years. As of 2022, the global Pulmonary Arterial Hypertension (Pah) Medicine market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to ......
  • Global Nifedipine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 04-Jan-2024        Price: US 3380 Onwards        Pages: 102
    Market Overview of Global Nifedipine market: According to our latest research, the global Nifedipine market looks promising in the next 5 years. As of 2022, the global Nifedipine market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Nifedipine market, with a systematical de......
  • Global Amlodipine Besylate Market Research Report 2024
    Published: 04-Jan-2024        Price: US 2900 Onwards        Pages: 115
    The Amlodipine Besylate market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Amlodipine Besylate market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profil......
  • Pulmonary Arterial Hypertension (PAH) Drugs - Global Market Insights and Sales Trends 2024
    Published: 25-Dec-2023        Price: US 3350 Onwards        Pages: 112
    The global Pulmonary Arterial Hypertension (PAH) Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Pulmonary Arterial Hypertension (PAH) Drugs in various end use industries. The expanding demands from the Hospitals, Clinics and Other,, are propelling Pulmonary Arterial Hypertension (PAH) Drugs market. Inhalation, one of the segments analysed in this report, is projected to record % ......
  • Captopril API - Global Market Insights and Sales Trends 2024
    Published: 25-Dec-2023        Price: US 3350 Onwards        Pages: 100
    The global Captopril API market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Captopril API in various end use industries. The expanding demands from the Captopril Tablet, Compound Captopril Tablet and Captopril Injection,, are propelling Captopril API market. 98% Captopril API, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the......
  • Telmisartan - Global Market Insights and Sales Trends 2024
    Published: 21-Dec-2023        Price: US 3350 Onwards        Pages: 107
    The global Telmisartan market size is expected to reach US$ 3631.3 million by 2029, growing at a CAGR of 3.4% from 2023 to 2029. The market is mainly driven by the significant applications of Telmisartan in various end use industries. The expanding demands from the Hospital, Clinic and Others,, are propelling Telmisartan market. Injection, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Freeze-Dried......
  • Global Ambrisentan Professional Survey Report 2023, Forecast to 2028
    Published: 20-Dec-2023        Price: US 3280 Onwards        Pages: 106
    Ambrisentan is a drug indicated for use in the treatment of pulmonary hypertension. The peptide endothelin constricts muscles in blood vessels, increasing blood pressure. Ambrisentan, which relaxes those muscles, is an endothelin receptor antagonist, and is selective for the type A endothelin receptor. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million US......
  • Global Ambrisentan Market Research Report 2023, Forecast to 2028
    Published: 20-Dec-2023        Price: US 2680 Onwards        Pages: 132
    Ambrisentan is a drug indicated for use in the treatment of pulmonary hypertension. The peptide endothelin constricts muscles in blood vessels, increasing blood pressure. Ambrisentan, which relaxes those muscles, is an endothelin receptor antagonist, and is selective for the type A endothelin receptor. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million US......
  • Global Amlodipine Besylate Professional Survey Report 2023, Forecast to 2028
    Published: 20-Dec-2023        Price: US 3280 Onwards        Pages: 133
    Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for each segment and sub-segment. This way, clients can achieve all their goals while taking advantage of emerging opportunities. Technological advancements, new product launches, and market capital flows are compared across scenarios to demonstrate their impact over the forecast period. D......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs